Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP
暂无分享,去创建一个
A. Dechaphunkul | T. Hortiwakul | S. Chusri | Pisud Siripaitoon | N. Pinpathomrat | Narongdet Kositpantawong | A. Navasakulpong | Smonrapat Surasombatpattana | Siripen Kanchanasuwan | W. Tanomkiat | Boonsri Charoenmak | Atthaphong Phongphithakchai | Nonthanat Tongsengkee | Nawamin Pinpathomrat
[1] Ploy N. Pratanwanich,et al. Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study , 2022, The Lancet Regional Health - Southeast Asia.
[2] D. H. Farkas,et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants , 2022, The Journal of infectious diseases.
[3] M. Stepanova,et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19 , 2022, BMC Infectious Diseases.
[4] M. Bhattacharya,et al. Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape , 2022, Folia Microbiologica.
[5] K. Khunti,et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study , 2022, BMJ.
[6] Yoshihiro Kitahara,et al. Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility , 2022, Respiratory Investigation.
[7] A. Vyse,et al. Hospitalization costs of adult community-acquired pneumonia in England , 2022, Journal of medical economics.
[8] C. Stephani,et al. Janus kinase inhibitors for the treatment of COVID-19. , 2022, The Cochrane database of systematic reviews.
[9] J. Skarbinski,et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.
[10] Boonsub Sakboonyarat,et al. Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital , 2022, Scientific Reports.
[11] P. Chaturvedi,et al. Outcomes of COVID-19 and risk factors in patients with cancer , 2022, Nature Cancer.
[12] J. Knight,et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.
[13] Michael C. McGee,et al. Mutations and Evolution of the SARS-CoV-2 Spike Protein , 2022, Viruses.
[14] S. Bhatt,et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.
[15] A. Apisarnthanarak,et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study , 2022, Emerging microbes & infections.
[16] K. Kahnert,et al. Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire , 2022, Respiratory Research.
[17] S. Murthy,et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial , 2022, Canadian Medical Association Journal.
[18] Yuemei Li,et al. The Impact of COVID-19 on Cancer , 2021, Infection and drug resistance.
[19] Janet S. Lee,et al. Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease , 2021, PLoS pathogens.
[20] C. Chakraborty,et al. D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin? , 2021, Molecular Therapy - Nucleic Acids.
[21] Peng Zheng,et al. N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2 , 2021, eLife.
[22] N. Skoetz,et al. Systemic corticosteroids for the treatment of COVID-19. , 2021, The Cochrane database of systematic reviews.
[23] Vineet D. Menachery,et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant , 2021, bioRxiv.
[24] Joshua B. Singer,et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.
[25] J. Rello,et al. COVID-19-Associated Pulmonary Aspergillosis (CAPA) , 2021, Journal of Intensive Medicine.
[26] E. Undurraga,et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.
[27] M. Khan,et al. Causes of hospitalization in the USA between 2005 and 2018 , 2021, European heart journal open.
[28] S. Maurer-Stroh,et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Navkiran K. Shokar,et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19 , 2021, Scientific Reports.
[30] I. Boutron,et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. , 2021, The Cochrane database of systematic reviews.
[31] K. Knox,et al. ACE2: At the crossroad of COVID-19 and lung cancer , 2021, Gene Reports.
[32] K. Badani,et al. Association between chronic kidney disease and COVID-19-related mortality in New York , 2021, World Journal of Urology.
[33] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[34] K. Rand,et al. Performance of a Semiquantitative Multiplex Bacterial and Viral PCR Panel Compared With Standard Microbiological Laboratory Results: 396 Patients Studied With the BioFire Pneumonia Panel , 2020, Open forum infectious diseases.
[35] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[36] O. Slabý,et al. Is the “Common Cold” Our Greatest Ally in the Battle Against SARS-CoV-2? , 2020, Frontiers in Cellular and Infection Microbiology.
[37] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[38] Christopher A. Lazarski,et al. SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein , 2020, Blood.
[39] Sheng Lin,et al. The chest CT features of coronavirus disease 2019 (COVID-19) in China: a meta-analysis of 19 retrospective studies , 2020, Virology journal.
[40] M. Lipsitch,et al. Cross-reactive memory T cells and herd immunity to SARS-CoV-2 , 2020, Nature Reviews Immunology.
[41] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[42] D. Kerr,et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.
[43] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[44] G. Cohen. Immune Dysfunction in Uremia 2020 , 2020, Toxins.
[45] Suqin Ben,et al. Meta‐analysis of chest CT features of patients with COVID‐19 pneumonia , 2020, Journal of medical virology.
[46] M. Djalali,et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.
[47] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[48] Hangyuan Guo,et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.
[49] A. Allard,et al. Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections , 2020, Infectious diseases.
[50] J. Rello,et al. Community-acquired bacterial pneumonia in adults: An update , 2020, The Indian journal of medical research.
[51] Robert J. Mason,et al. Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.
[52] G. Lippi,et al. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection , 2020, International Urology and Nephrology.
[53] Han Zhang,et al. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis , 2020, Journal of the American College of Radiology.
[54] Tian Huang,et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.
[55] Michael Roth,et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.
[56] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[57] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[58] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[59] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[60] Ralph S. Baric,et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.
[61] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[62] Z. Memish,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.
[63] M. Fine,et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.
[64] A. Pfeiffer,et al. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation , 2019, Immunity & Ageing.
[65] William A. Mattingly,et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] K. Huh,et al. Community-Acquired Pneumonia in the Asia-Pacific Region , 2016, Seminars in Respiratory and Critical Care Medicine.
[67] M. Ebell,et al. Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis , 2016, The Annals of Family Medicine.
[68] D. Chung,et al. Community-acquired pneumonia requiring hospitalization among U . S . adults , 2016 .
[69] Á. Gentile. [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination]. , 2014, Archivos argentinos de pediatria.
[70] Y. Thavornpitak,et al. Burden of adult pneumonia in Thailand: a nationwide hospital admission data 2010. , 2014, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[71] Lauren M Wier,et al. Costs for Hospital Stays in the United States, 2010 , 2013 .
[72] T. Schaberg,et al. Guidelines for the management of adult lower respiratory tract infections ‐ Full version , 2011, Clinical Microbiology and Infection.
[73] C. Esquinas,et al. Microbial aetiology of community-acquired pneumonia and its relation to severity , 2011, Thorax.
[74] Margaret A Dudeck,et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.
[75] A. Anzueto,et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.
[76] M. Afzal. Health research in the World Health Organization Regional Office for the Eastern Mediterranean. , 2008, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[77] S. Lochindarat,et al. Prevalence and clinical presentations of atypical pathogens infection in community acquired pneumonia in Thailand. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[78] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[79] J. M. Martínez Vázquez,et al. Etiology of community-acquired pneumonia , 2005, European Journal of Clinical Microbiology.
[80] Gilles Clermont,et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. , 2002, American journal of respiratory and critical care medicine.
[81] P. Brown,et al. Community-acquired pneumonia: An overview , 1999, Current infectious disease reports.
[82] C. Ellenbogen. The common cold. , 1981, American family physician.